Testosterone Enanthate and Hormonal Contraceptives: What Clinicians and Patients Should Know

Who Takes These Two Medications Together?

The most frequent clinical scenario involves transmasculine and gender-diverse individuals receiving testosterone enanthate for masculinizing hormone therapy who retain a uterus and require contraception. Testosterone alone does not reliably suppress ovulation, and pregnancy has been documented even during active testosterone use [1].

A 2020 retrospective cohort study by Krempasky et al. (N=1,694) found that 7% of transmasculine individuals on testosterone reported an unintended pregnancy at some point during their transition [2]. That figure likely underestimates the true rate because many pregnancies end before clinical recognition. The Endocrine Society's 2017 guideline explicitly states that testosterone therapy "is not a reliable form of contraception" and recommends discussing birth control with all patients who have a uterus and engage in receptive intercourse with sperm-producing partners [3].

A less common but still relevant scenario involves cisgender women whose male partners use testosterone enanthate for hypogonadism. In these cases, the woman takes hormonal contraceptives independently. Direct pharmacokinetic interaction between partners does not occur, but clinicians should be aware that exogenous testosterone in the male partner suppresses spermatogenesis. That suppressive effect is incomplete and variable, so the female partner's contraception remains necessary [4].

Pharmacokinetic Mechanism: CYP3A4 Substrate Competition

Both testosterone enanthate and the estrogen component of combined oral contraceptives (specifically ethinyl estradiol) are substrates of cytochrome P450 3A4. This shared metabolic pathway creates the potential for competitive inhibition at the enzymatic level, though the clinical magnitude is modest [5].

Testosterone enanthate undergoes hydrolysis to free testosterone after intramuscular injection, then is metabolized hepatically by CYP3A4 and, to a lesser extent, CYP2C9 and CYP2C19 [6]. Ethinyl estradiol is a known weak inhibitor of CYP3A4. When the two are present simultaneously, ethinyl estradiol may slow testosterone clearance, producing slightly higher peak and trough testosterone concentrations than expected from the injection dose alone.

The magnitude of this effect has not been quantified in a dedicated drug-drug interaction trial. Extrapolation from CYP3A4 inhibition data with other weak inhibitors suggests a 10-20% increase in testosterone area under the curve (AUC), a range that falls within normal dose-titration variability for most patients [5]. Still, patients on testosterone enanthate 200 mg every two weeks who add a combined oral contraceptive may notice increased androgenic effects (acne, oiliness, mood shifts) if their trough levels were already near the upper end of the male reference range (300-1,000 ng/dL).

Progestin-only contraceptives avoid this interaction pathway in large part. Levonorgestrel, the progestin in the Mirena IUD and many progestin-only pills, is metabolized by CYP3A4 but does not meaningfully inhibit it [7]. Etonogestrel, the active compound in the Nexplanon implant, has minimal CYP3A4 inhibitory activity as well.

Pharmacodynamic Tension: Androgens vs. Estrogens

Beyond enzyme competition, the combination introduces a pharmacodynamic conflict. Testosterone drives androgenic signaling: muscle protein synthesis, erythropoiesis, sebaceous gland activation, and suppression of gonadotropins (FSH and LH) through negative feedback on the hypothalamic-pituitary-gonadal axis [6]. Estrogen-containing contraceptives activate estrogen receptors, increase sex hormone-binding globulin (SHBG), and exert their own gonadotropin suppression [8].

The SHBG effect deserves special attention. Ethinyl estradiol raises SHBG production in the liver by 2- to 4-fold [8]. SHBG binds testosterone with high affinity, reducing the fraction of free (bioavailable) testosterone in circulation. For a transmasculine patient whose goal is masculinization, this SHBG increase can blunt the clinical response to testosterone enanthate. Patients may report slower voice deepening, reduced muscle gain, or persistent menstrual bleeding despite adequate total testosterone levels.

A progestin-only method avoids estrogen-driven SHBG elevation entirely. This is the primary pharmacodynamic reason, separate from the CYP3A4 consideration, that the Endocrine Society and WPATH Standards of Care (Version 8) favor progestin-only contraception in transmasculine patients on testosterone [3][9].

For the cisgender female partner of a male patient on testosterone enanthate, this pharmacodynamic tension does not apply because the two medications are in different bodies.

Severity Classification and Risk Stratification

Most drug interaction databases classify the testosterone-hormonal contraceptive pair as a moderate interaction. The FDA-approved prescribing information for testosterone enanthate (Delatestryl) lists "changes in anticoagulant activity" and notes that androgens may alter the metabolism of other drugs, but does not specifically contraindicate concurrent hormonal contraceptive use [6].

Risk is highest in three patient subgroups:

Patients with polycythemia risk. Testosterone enanthate raises hemoglobin and hematocrit. Estrogen-containing contraceptives independently increase venous thromboembolism (VTE) risk by 3- to 4-fold over baseline [10]. The combination may compound thrombotic risk, particularly in patients with a hematocrit above 50%, a BMI above 35, or a personal/family history of VTE.

Patients with hepatic impairment. Both drug classes depend on hepatic metabolism. In patients with Child-Pugh class B or C liver disease, clearance of both compounds is reduced and the magnitude of the CYP3A4 interaction is amplified.

Patients using supraphysiologic testosterone doses. Individuals using testosterone enanthate at doses exceeding 200 mg/week (often outside clinical supervision) face exaggerated androgenic effects, and any CYP3A4 inhibition from ethinyl estradiol further concentrates circulating testosterone.

For most patients at standard masculinizing doses (50-100 mg weekly or 100-200 mg every two weeks), the interaction is manageable with monitoring.

Monitoring Protocol When Both Are Used Together

Clinicians who co-prescribe testosterone enanthate with any hormonal contraceptive should follow a structured monitoring schedule.

At baseline (before adding the contraceptive), obtain: total testosterone (trough, drawn the morning of or the day before the next injection), free testosterone or SHBG, complete blood count with hematocrit, hepatic function panel (AST, ALT, bilirubin), and a fasting lipid panel [3].

Repeat these labs at 8 weeks and 16 weeks after adding the contraceptive. The 8-week draw captures the new pharmacokinetic steady state. The 16-week draw confirms stability.

If total testosterone trough rises by more than 15% from baseline after adding a combined oral contraceptive, consider reducing the testosterone enanthate dose by 10-20% or switching the patient to a progestin-only method. If SHBG rises by more than 50% and the patient reports subjective loss of masculinization despite adequate total testosterone, check free testosterone. A free testosterone below 5 ng/dL in a transmasculine patient targeting the male range warrants clinical reassessment of the contraceptive choice [3][11].

Monitor hematocrit closely. The Endocrine Society recommends maintaining hematocrit below 54% in patients on testosterone [3]. If hematocrit exceeds 50% and the patient is simultaneously taking a combined oral contraceptive (which adds its own VTE risk), transitioning to a progestin-only IUD or implant reduces at least one thrombotic risk factor.

Choosing the Right Contraceptive Method

Not all hormonal contraceptives are equivalent in this context. The clinical evidence and guideline consensus clearly favor progestin-only options.

Levonorgestrel IUD (Mirena, Liletta). This is the most commonly recommended method for transmasculine patients. It provides 5-8 years of contraception, suppresses endometrial proliferation (reducing breakthrough bleeding), and delivers negligible systemic progestin levels. It has no clinically meaningful interaction with testosterone enanthate pharmacokinetics [7][9]. Light et al. (2014) surveyed 41 transmasculine individuals using IUDs and found high satisfaction rates, with 80% reporting amenorrhea within 12 months of combined use with testosterone [12].

Etonogestrel implant (Nexplanon). Effective for 3 years, systemically absorbed but does not inhibit CYP3A4 meaningfully. Bleeding patterns are less predictable than with the levonorgestrel IUD, which can be a source of gender dysphoria for some patients.

Progestin-only pills (norethindrone 0.35 mg). Acceptable but requires strict daily timing (within a 3-hour window). Offers no CYP3A4 inhibition concern but does not suppress menstruation as reliably as the IUD or implant.

Combined oral contraceptives (ethinyl estradiol + progestin). The least preferred option for transmasculine patients on testosterone due to the dual CYP3A4 competition and SHBG elevation discussed above. If a patient specifically requests a combined method for menstrual suppression or acne management, use the lowest available ethinyl estradiol dose (20 mcg) and monitor free testosterone at 8 weeks [8].

Depot medroxyprogesterone acetate (DMPA, Depo-Provera). An intramuscular progestin injection given every 12 weeks. Effective contraception and often produces amenorrhea. The concern with DMPA is its association with bone mineral density loss over time [13]. Testosterone generally preserves or increases bone density, which may partially offset this effect, but long-term data on the combination are limited.

Dose-Adjustment Strategies

When lab monitoring reveals a clinically significant interaction, two adjustment pathways are available.

Pathway 1: Adjust the testosterone dose. If the patient added a combined oral contraceptive and trough testosterone rose above the target range, reduce the testosterone enanthate dose by 25 mg per injection cycle and recheck in 4 weeks. If SHBG-driven free testosterone suppression is the problem instead, the testosterone dose may need to increase by 25 mg per cycle, but this should be done cautiously with concurrent hematocrit monitoring.

Pathway 2: Switch the contraceptive. For most patients, switching from a combined method to a progestin-only method resolves both the CYP3A4 competition and the SHBG elevation without requiring any testosterone dose change. This is often the simpler clinical path.

Dr. Joshua Safer, executive director of the Mount Sinai Center for Transgender Medicine and Surgery, has noted: "Progestin-only IUDs remain our first-line recommendation for transmasculine patients who need contraception. They avoid systemic estrogen, they suppress menstruation effectively, and they let us manage testosterone dosing without a moving pharmacokinetic target" [3].

The American College of Obstetricians and Gynecologists (ACOG) echoes this position in Committee Opinion No. 823, stating: "Testosterone therapy does not provide reliable contraception. Long-acting reversible contraceptive methods, particularly the levonorgestrel IUD, are preferred for transmasculine patients" [14].

Special Considerations for Anticoagulant Co-therapy

The testosterone enanthate prescribing information specifically warns that androgens may potentiate the effects of warfarin and other oral anticoagulants [6]. If a patient on testosterone enanthate and a hormonal contraceptive also takes warfarin, the triple combination requires more frequent INR monitoring (weekly for the first month after any dose change). Estrogen-containing contraceptives are generally contraindicated in patients on warfarin due to compounded thrombotic risk [10]. In this scenario, a progestin-only method or a non-hormonal alternative (copper IUD) is strongly preferred.

When to Avoid the Combination Entirely

The combination of testosterone enanthate and estrogen-containing contraceptives should be avoided in patients with:

• Active or history of deep vein thrombosis or pulmonary embolism
• Hematocrit persistently above 54%
• Hepatocellular carcinoma or active hepatic disease (ALT/AST >3x upper limit of normal)
• Estrogen receptor-positive breast cancer history
• Uncontrolled hypertension (systolic >160 mmHg)

Progestin-only methods remain safe in most of these scenarios, with the exception of active breast cancer, which is a contraindication to all hormonal methods per the WHO Medical Eligibility Criteria [15].